Edition:
United Kingdom

BioLife Solutions Inc (BLFS.OQ)

BLFS.OQ on NASDAQ Stock Exchange Capital Market

8.91USD
18 May 2018
Change (% chg)

$-0.15 (-1.66%)
Prev Close
$9.06
Open
$9.05
Day's High
$9.21
Day's Low
$8.83
Volume
26,849
Avg. Vol
20,907
52-wk High
$9.21
52-wk Low
$2.13

Latest Key Developments (Source: Significant Developments)

BioLife Solutions Reports Q1 Loss Per Share $0.01
Thursday, 10 May 2018 

May 10 (Reuters) - BioLife Solutions Inc ::BIOLIFE SOLUTIONS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.01.Q1 REVENUE ROSE 61 PERCENT TO $3.8 MILLION.AFFIRMING BIOPRESERVATION MEDIA REVENUE IS NOW EXPECTED TO RANGE BETWEEN $14.5 MILLION TO $15.5 MILLION FOR 2018.AFFIRMING FULL-YEAR GAAP OPERATING PROFIT, WITH PROPORTIONAL INCREASES IN ADJUSTED EBITDA AND CASH FLOW FROM OPERATIONS.INCREASING 2018 GROSS MARGIN GUIDANCE TO 63% TO 65%.  Full Article

BioLife Solutions Q4 Loss Per Share $0.05
Thursday, 8 Mar 2018 

March 8 (Reuters) - BioLife Solutions Inc ::BIOLIFE SOLUTIONS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.05.REAFFIRMS GUIDANCE FOR 2018 OPERATING PROFIT.QTRLY REVENUE $3.1 MILLION VERSUS $2.3 MILLION.  Full Article

Biolife Solutions Announces Preliminary 2017 Revenue Increase Of 34% To $11 Million
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Biolife Solutions Inc ::BIOLIFE SOLUTIONS ANNOUNCES PRELIMINARY 2017 REVENUE INCREASE OF 34% TO $11 MILLION.Q4 REVENUE ROSE 39 PERCENT TO $3.1 MILLION.- FOR FULL YEAR 2017, PRELIMINARY REVENUE WAS $11 MILLION, A 34% INCREASE FROM 2016.- IN 2018, GROSS MARGIN IS EXPECTED TO RANGE BETWEEN 62% TO 64%.BIOLIFE SOLUTIONS - ‍FOR FY18 BIOPRESERVATION MEDIA REVENUE IS EXPECTED TO RANGE $13.6 MILLION -$14.7 MILLION, REPRESENTING GROWTH OF 25% TO 35% OVER 2017​.  Full Article

Biolife Solutions Executes Supply Agreement With Iovance Biotherapeutics
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Biolife Solutions Inc ::BIOLIFE SOLUTIONS EXECUTES SUPPLY AGREEMENT WITH IOVANCE BIOTHERAPEUTICS.BIOLIFE SOLUTIONS - EXECUTED AGREEMENT TO SUPPLY CRYOSTOR CELL FREEZE MEDIA AND HYPOTHERMOSOL STORAGE AND SHIPPING MEDIA TO IOVANCE BIOTHERAPEUTICS.  Full Article

BioLife Solutions posts Q3 loss per share $0.03
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - BioLife Solutions Inc :Biolife Solutions announces third quarter 2017 financial results.Q3 loss per share $0.03.Biolife Solutions Inc - ‍gross margin for Q3 of 2017 was 63 pct compared with 57 pct in Q3 of 2016​.Biolife Solutions Inc - ‍2017 revenue is expected to range between $10.8 million to $11 million​.Biolife Solutions Inc - ‍2017 gross margin is expected to be between 60 pct and 62 pct​.Biolife Solutions Inc - qtrly ‍revenue $2.96 million versus $2.1 million.  Full Article

Biolife Solutions Q2 loss per share $0.06
Thursday, 10 Aug 2017 

Aug 10 (Reuters) - Biolife Solutions Inc ::Biolife solutions announces second quarter 2017 financial results.Expects FY 2017 revenue in excess of $10 million.Q2 loss per share $0.06.Biolife Solutions Inc says reaffirms full-year revenue guidance for biopreservation media products.  Full Article

BioLife Solutions qtrly product sales $1.99 mln
Thursday, 11 Aug 2016 

BioLife Solutions Inc : Q2 revenue rose 33 percent . BioLife Solutions reports results for second quarter 2016 . Sees FY 2016 revenue more than $8.0 million . Qtrly basic and diluted net loss per common share attributable to BioLife Solutions, Inc. $0.11 .Qtrly product sales $1.99 million versus $1.5 million a year ago.  Full Article

Biolife solutions executes 10 year supply agreement with Bellicum Pharmaceuticals for CryoStor use in cellular immunotherapies
Wednesday, 10 Aug 2016 

BioLife Solutions Inc :Biolife solutions executes 10 year supply agreement with Bellicum Pharmaceuticals for CryoStor® use in cellular immunotherapies.  Full Article

Biolife Solutions says entered into 10-year supply agreement with Kite Pharma
Monday, 11 Jul 2016 

Biolife Solutions Inc : Biolife solutions executes 10 year supply agreement with kite pharma for Cryostor use in CAR T cell therapies . Agreement provides for Kite's supply of Biolife's Cryostor clinical grade freeze media for cells and tissues .Says entered into a ten year supply agreement with Kite Pharma.  Full Article

BRIEF-Casdin Capital To Become Shareholder In Biolife Solutions

* CASDIN CAPITAL LLC, ENTERED INTO AN AGREEMENT TO PURCHASE 1,000,000 BIOLIFE SOLUTIONS SHARES IN PRIVATE DEAL Source text for Eikon: Further company coverage: